<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EDLUAR- zolpidem tartrateÂ tabletÂ </strong><br>Meda Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use EDLUAR safely and effectively. See full prescribing information for EDLUAR.<br><br>
			Edluar<span class="Sup">Â®</span> (zolpidem tartrate) sublingual tablets, for oral use CIV</span><br>
		Initial U.S. Approval: 1992
	</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Edluar (zolpidem tartrate) sublingual tablets, a gamma-aminobutyric acid (GABA) A agonist, is indicated for the short-term treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulties with sleep initiation. Zolpidem tartrate has been shown to decrease sleep latency for up to 35 days in controlled clinical studies.  (<a href="#KS010de965605-268a-4479-86f7-84de949cf36f">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Use the lowest dose effective for the patient (<a href="#KS021de965605-268a-4479-86f7-84de949cf36f">2.1</a>)</li>
<li>Recommended dose is 5 mg for women and 5 or 10 mg for men, immediately before bedtime (<a href="#KS021de965605-268a-4479-86f7-84de949cf36f">2.1</a>)</li>
<li>Geriatric patients and patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>: Recommended dose is 5 mg for men and women (<a href="#KS022de965605-268a-4479-86f7-84de949cf36f">2.2</a>)</li>
<li>Lower doses of CNS depressants may be necessary when taken concomitantly with Edluar (<a href="#KS023de965605-268a-4479-86f7-84de949cf36f">2.3</a>)</li>
<li>Co-administration with CNS depressants:  Recommended dose is 5 mg for men and women (<a href="#KS023de965605-268a-4479-86f7-84de949cf36f">2.3</a>)</li>
<li>The effect of Edluar may be slowed if taken with or immediately after a meal (<a href="#KS024de965605-268a-4479-86f7-84de949cf36f">2.4</a>)</li>
<li>Edluar sublingual tablet should be placed under the tongue, where it will disintegrate (<a href="#KS024de965605-268a-4479-86f7-84de949cf36f">2.4</a>)
										The tablet should not be swallowed and the tablet should not be taken with water (<a href="#KS024de965605-268a-4479-86f7-84de949cf36f">2.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Sublingual tablets: 5 mg and 10 mg. Tablets <span class="Underline">not</span> scored. (<a href="#KS030de965605-268a-4479-86f7-84de949cf36f">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolpidem (<a href="#KS040de965605-268a-4479-86f7-84de949cf36f">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>CNS depressant effects: Impairs alertness and motor coordination. Instruct patients on correct use.  (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>)</li>
<li>Need to evaluate for co-morbid diagnosis: Reevaluate if <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> persists after 7 to 10 days of use.  (<a href="#KS052de965605-268a-4479-86f7-84de949cf36f">5.2</a>)</li>
<li>Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported. Do not rechallenge if such reactions occur.  (<a href="#KS053de965605-268a-4479-86f7-84de949cf36f">5.3</a>)</li>
<li>â€œSleep-drivingâ€? and other complex behaviors while not fully awake. Risk increases with dose and use with other CNS depressants and alcohol. Immediately evaluate any new onset behavioral changes.  (<a href="#KS054de965605-268a-4479-86f7-84de949cf36f">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>: Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidal thinking may occur. Prescribe the least amount of tablets feasible to avoid <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdose</span>. (<a href="#KS055de965605-268a-4479-86f7-84de949cf36f">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>: Consider this risk before prescribing in patients with compromised respiratory function. (<a href="#KS056de965605-268a-4479-86f7-84de949cf36f">5.6</a>)</li>
<li>Withdrawal effects: Symptoms may occur with rapid dose reduction or discontinuation. (<a href="#KS0d4ad60-adb3-11e2-9e96-0800200c9a66">5.7</a>, <a href="#KS093de965605-268a-4479-86f7-84de949cf36f">9.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most commonly observed adverse reactions were: </p>
<dl>
<dt>Â </dt>
<dd>Short-term (&lt; 10 nights): <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>Â </dt>
<dd>Long-term (28 - 35 nights): <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and drugged feelings (<a href="#KS061de965605-268a-4479-86f7-84de949cf36f">6.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact  Meda Pharmaceuticals Inc. at 1-866-444-7799 or FDA at 1-800-FDA-1088 or <span class="Italics Underline">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>CNS-depressants, including alcohol: Possible adverse additive CNS-depressant effects (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>, <a href="#KS071de965605-268a-4479-86f7-84de949cf36f">7.1</a>)</li>
<li>Imipramine: decreased alertness observed (<a href="#KS071de965605-268a-4479-86f7-84de949cf36f">7.1</a>)</li>
<li>Chlorpromazine: impaired alertness and psychomotor performance observed (<a href="#KS071de965605-268a-4479-86f7-84de949cf36f">7.1</a> )</li>
<li>Rifampin: combination use may decrease effects (<a href="#KS072de965605-268a-4479-86f7-84de949cf36f">7.2</a>) </li>
<li>Ketoconazole: combination use may increase effect (<a href="#KS072de965605-268a-4479-86f7-84de949cf36f">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Based on animal data, may cause fetal harm.  (<a href="#KS081de965605-268a-4479-86f7-84de949cf36f">8.1</a>)</li>
<li>Pediatric use: Safety and effectiveness not established. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> (incidence rate 7%) and other psychiatric and/or nervous system adverse reactions were observed frequently in a study of pediatric patients with Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder. (<a href="#KS054de965605-268a-4479-86f7-84de949cf36f">5.4</a>, <a href="#KS084de965605-268a-4479-86f7-84de949cf36f">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage in Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Special Populations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Use with CNS Depressants</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Administration</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 CNS Depressant Effects and Next-Day Impairment</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Need to Evaluate for Co-morbid Diagnoses</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Severe Anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal Thinking</span> and Behavioral Changes </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Use in Patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Withdrawal Effects</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CNS-active Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs That Affect Drug Metabolism Via Cytochrome P450</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2  Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Gender Difference in Pharmacokinetics</a></h2>
<h1><a href="#section-9" class="toc">9  DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1  Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2  Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3  <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10  OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Signs and Symptoms</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Recommended Treatment</a></h2>
<h1><a href="#section-11" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Transient Insomnia</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Chronic Insomnia</span> </a></h2>
<h2><a href="#section-14.3" class="toc">14.3 Studies Pertinent to Safety Concerns for Sedative/Hypnotic Drugs </a></h2>
<h1><a href="#section-15" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="KS010de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">Edluar (zolpidem tartrate) sublingual tablets are indicated for the short-term treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulties with sleep initiation <span class="Italics">[see Clinical Studies (<a href="#KS140de965605-268a-4479-86f7-84de949cf36f">14</a>)]</span>.</p>
<p>The clinical trials performed with Zolpidem tartrate in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="KS020de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="KS021de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage in Adults</h2>
<p class="First">Use the lowest effective dose for the patient. The recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. If the 5 mg dose is not effective, the dose can be increased to 10 mg. In some patients, the higher morning blood levels following use of the 10 mg dose increase the risk of next day impairment of driving and other activities that require full alertness <span class="Italics">[see Warnings and Precautions (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>)]</span>.  The total dose of Edluar should not exceed 10 mg once daily immediately before bedtime.</p>
<p>The recommended initial doses for women and men are different because zolpidem clearance is lower in women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS022de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Special Populations</h2>
<p class="First">Elderly or debilitated patients may be especially sensitive to the effects of zolpidem tartrate. Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> do not clear the drug as rapidly as normal subjects. The recommended dose of Edluar in both of these patient populations is 5 mg once daily immediately before bedtime <span class="Italics">[see Warnings and Precautions (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>); Use in Specific Populations (<a href="#KS085de965605-268a-4479-86f7-84de949cf36f">8.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS023de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Use with CNS Depressants</h2>
<p class="First">Dosage adjustment may be necessary when Edluar is combined with other CNS-depressant drugs because of the potentially additive effects <span class="Italics">[see Warnings and Precautions (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS024de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Administration</h2>
<p class="First">The effect of Edluar may be slowed by ingestion with or immediately after a meal. </p>
<p>Edluar sublingual tablet should be placed under the tongue, where it will disintegrate.  The tablet should not be swallowed and the tablet should not be taken with water.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="KS030de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Edluar is available in 5 mg and 10 mg strength tablets for sublingual administration.  Tablets are <span class="Underline">not</span> scored.</p>
<p>Edluar 5 mg sublingual tablets are round white, flat-faced, bevel-edged, with debossed V on one side.</p>
<p>Edluar 10 mg sublingual tablets are round white, flat-faced, bevel-edged, with debossed X on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="KS040de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">Edluar is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolpidem. Observed reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> <span class="Italics">[see Warnings and Precautions (<a href="#KS053de965605-268a-4479-86f7-84de949cf36f">5.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="KS050de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="KS051de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-5.1"></a><p></p>
<h2>5.1 CNS Depressant Effects and Next-Day Impairment</h2>
<p class="First">Edluar, like other sedative-hypnotic drugs, has central nervous system (CNS) depressant effects.  Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.  Dosage adjustments of Edluar and of other concomitant CNS depressants may be necessary when Edluar is administered with such agents because of the potentially additive effects. The use of Edluar with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended <span class="Italics">[see Dosage and Administration (<a href="#KS023de965605-268a-4479-86f7-84de949cf36f">2.3</a>)]</span>.</p>
<p>The risk of next-day psychomotor impairment, including impaired driving, is increased if Edluar is taken with less than a full night of sleep remaining (7 to 8 hours); if a higher than the recommended dose is taken; if co-administered with other CNS depressants; or if co-administered with other drugs that increase the blood level of zolpidem.  Patients should be cautioned against driving and other activities requiring complete mental alertness if Edluar is taken in these circumstances. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS052de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Need to Evaluate for Co-morbid Diagnoses</h2>
<p class="First">Because <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> should be initiated only after a careful evaluation of the patient. The failure of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including zolpidem.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS053de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Severe Anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> </h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including zolpidem tartrate. Some patients have had additional symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, throat closing or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that suggest <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Some patients have required medical therapy in the emergency department. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involves the throat, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> after treatment with Edluar should not be rechallenged with the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS054de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal Thinking</span> and Behavioral Changes </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavior changes have been reported in patients treated with sedative/hypnotics, including zolpidem. Some of these changes included decreased inhibition (e.g. <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span> and extroversion that seemed out of character), <span class="product-label-link" type="condition" conceptid="4092397" conceptname="Bizarre behavior">bizarre behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>. Visual and <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">auditory hallucinations</span> have been reported.</p>
<p>In controlled trials of zolpidem tartrate 10 mg taken at bedtime, &lt;1% of adults with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> who received zolpidem reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. In a clinical trial, 7% of pediatric patients treated with zolpidem tartrate 0.25 mg/kg taken at bedtime reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, versus 0% treated with placebo <span class="Italics">[see Use in Specific Populations (<a href="#KS084de965605-268a-4479-86f7-84de949cf36f">8.4</a>)]</span>.</p>
<p>Complex behaviors such as â€œsleep-drivingâ€? (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> for the event) have been reported in sedative-hypnotic-naive as well as in sedative-hypnotic-experienced persons. Although behaviors such as â€œsleep-drivingâ€? have occurred with zolpidem alone at therapeutic doses, the co-administration of zolpidem with alcohol or other CNS depressants increases the risk of such behaviors, as does the use of Edluar at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of Edluar should be strongly considered for patients who report a â€œsleep-drivingâ€? episode.</p>
<p>Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with â€œsleep-drivingâ€?, patients usually do not remember these events. <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and other neuro-<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> may also occur. </p>
<p>It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder.  Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS055de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Use in Patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">In primarily depressed patients treated with sedative-hypnotics, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and suicidal thoughts and actions (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>), have been reported.  Suicidal tendencies may be present in such patients and protective measures may be required.  Intentional overdosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS056de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">Although studies with 10 mg zolpidem tartrate did not reveal respiratory depressant effects at hypnotic doses in healthy subjects or in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), a reduction in the Total Arousal Index, together with a reduction in lowest oxygen saturation and increase in the time of oxygen desaturation below 80% and 90%, was observed in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> when treated with zolpidem compared to placebo.  Since sedative-hypnotics have the capacity to depress respiratory drive, precautions should be taken if Edluar is prescribed to patients with compromised respiratory function.  Post-marketing reports of <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span> in patients receiving 10 mg of zolpidem tartrate, most of whom had pre-existing respiratory impairment, have been reported.  The risks of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> should be considered prior to prescribing Edluar in patients with respiratory impairment including <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS0d4ad60-adb3-11e2-9e96-0800200c9a66"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Withdrawal Effects</h2>
<p class="First">There have been reports of withdrawal signs and symptoms following the rapid dose decrease or abrupt discontinuation of zolpidem.  Monitor patients for tolerance, abuse, and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> <span class="Italics">[see Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#KS092de965605-268a-4479-86f7-84de949cf36f">9.2</a>) and (<a href="#KS093de965605-268a-4479-86f7-84de949cf36f">9.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="KS060de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li>CNS-depressant effects and next-day impairment  <span class="Italics">[see Warnings and Precautions (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>)]</span>
</li>
<li>Serious anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>  <span class="Italics">[see Warning and Precautions (<a href="#KS053de965605-268a-4479-86f7-84de949cf36f">5.3</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavior changes, and complex behaviors  <span class="Italics">[see Warning and Precautions (<a href="#KS054de965605-268a-4479-86f7-84de949cf36f">5.4</a>)]</span>
</li>
<li>Withdrawal effects <span class="Italics">[see Warning and Precautions (<a href="#KS0d4ad60-adb3-11e2-9e96-0800200c9a66">5.7</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="KS061de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Bold Italics">Associated with discontinuation of treatment:</span></p>
<p>Approximately 4% of 1,701 patients who received zolpidem tartrate at all doses (1.25 to 90 mg) in U.S. premarketing clinical trials discontinued treatment because of an adverse reaction. Reactions most commonly associated with discontinuation from U.S. trials were daytime <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> (0.5%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.4%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.6%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.5%).</p>
<p>Approximately 4% of 1,959 patients who received zolpidem tartrate at all doses (1 to 50 mg) in similar foreign trials discontinued treatment because of an adverse reaction. Reactions most commonly associated with discontinuation from these trials were daytime <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> (1.1%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (0.8%), <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> (0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.4%), and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> (0.4%).</p>
<p>Data from a clinical study in which selective serotonin reuptake inhibitor (SSRI)-treated patients were given zolpidem tartrate revealed that four of the seven discontinuations during double-blind treatment with zolpidem (n=95) were associated with impaired concentration, continuing or aggravated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>; one patient treated with placebo (n=97) was discontinued after an <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span>.</p>
<p><span class="Bold Italics">Most commonly observed adverse reactions in controlled trials:</span></p>
<p>During short-term treatment (up to 10 nights) with zolpidem tartrate at doses up to 10 mg, the most commonly observed adverse reactions associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> (reported by 2% of zolpidem patients), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (1%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1%). During longer-term treatment (28 to 35 nights) with zolpidem tartrate at doses up to 10 mg, the most commonly observed adverse reactions associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (5%) and drugged feelings (3%).</p>
<p><span class="Bold Italics">Adverse reactions observed at an incidence of â‰¥1% in controlled trials:</span></p>
<p>The following tables enumerate treatment-emergent adverse event frequencies that were observed at an incidence equal to 1% or greater among patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> who received zolpidem tartrate and at a greater incidence than placebo in U.S. placebo-controlled trials. Events reported by investigators were classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms for the purpose of establishing event frequencies. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in these clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigators involving related drug products and uses, since each group of drug trials is conducted under a different set of conditions. However, the cited figures provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the population studied. </p>
<p>The following table was derived from a pool of 11 placebo-controlled short-term U.S. efficacy trials involving zolpidem in doses ranging from 1.25 to 20 mg. The table is limited to data from doses up to and including 10 mg, the highest dose recommended for use.</p>
<table>
<caption><span>TABLE 1: Incidence of Treatment-Emergent Adverse Experiences in
										Placebo-Controlled Clinical Trials with zolpidem tartrate lasting up to 10 nights 
										(Percentage of patients reporting)
									</span></caption>
<tfoot><tr class="First Last"><td colspan="3">*Reactions reported by at least 1% of patients treated with oral zolpidem and at a greater frequency than placebo.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Body System/<br>
												Adverse Event*</span></td>
<td align="center"><span class="Bold">Zolipidem tartrate<br>
												(â‰¤ 10 mg)<br>
												(N=685)</span></td>
<td align="center"><span class="Bold">Placebo<br><br>
												(N=473)</span></td>
</tr>
<tr>
<td><span class="Bold">Central and Peripheral Nervous System</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">7</td>
<td align="center">6</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td align="center">2</td>
<td align="center">-</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">1</td>
<td align="center">-</td>
</tr>
<tr>
<td>Â </td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="Bold">Gastrointestinal System</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">1</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
<p>The following table was derived from a pool of three placebo-controlled long-term efficacy trials involving oral zolpidem. These trials involved patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> who were treated for 28 to 35 nights with zolpidem at doses of 5, 10, or 15 mg. The table is limited to data from doses up to and including 10 mg, the highest dose recommended for use. The table includes only adverse events occurring at an incidence of at least 1% for zolpidem patients.</p>
<table>
<caption><span>TABLE 2: Incidence of Treatment-Emergent Adverse Experiences in
										Placebo-Controlled Clinical Trials with zolpidem tartrate lasting up to 35 nights 
										(Percentage of patients reporting)
									</span></caption>
<tfoot><tr class="First Last"><td colspan="3">*Reactions reported by at least 1% of patients treated with oral zolpidem and at a greater frequency than placebo.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Body System/<br>
												Adverse Event*</span></td>
<td align="center"><span class="Bold">Zolpidem tartrate<br>
												(â‰¤ 10 mg)<br>
												(N=152)</span></td>
<td align="center"><span class="Bold">Placebo<br><br>
												(N=161)</span></td>
</tr>
<tr>
<td><span class="Bold">Autonomic Nervous System</span></td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td>
<br><span class="Bold">Body as a Whole</span>
</td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></td>
<td align="center">4</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td align="center">2</td>
<td align="center">-</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td align="center">1</td>
<td align="center">-</td>
</tr>
<tr>
<td>
<br><span class="Bold">Cardiovascular System</span>
</td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></td>
<td align="center">2</td>
<td align="center">-</td>
</tr>
<tr>
<td>
<br><span class="Bold">Central and Peripheral Nervous System</span>
</td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td align="center">8</td>
<td align="center">5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">5</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td>Drugged feeling</td>
<td align="center">3</td>
<td align="center">-</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></td>
<td align="center">1</td>
<td align="center">-</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td align="center">1</td>
<td align="center">-</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep disorder</span></td>
<td align="center">1</td>
<td align="center">-</td>
</tr>
<tr>
<td>
<br><span class="Bold">Gastrointestinal System</span>
</td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td>
<br><span class="Bold">Respiratory System</span>
</td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">4</td>
<td align="center">2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td>
<br><span class="Bold">Skin and Appendages</span>
</td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics">Dose relationship for adverse reactions associated with oral zolpidem:</span></p>
<p>There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse reactions associated with oral zolpidem use, particularly for certain CNS and gastrointestinal adverse events. </p>
<p><span class="Bold Italics">Oral tissue-related adverse reactions to Edluar:</span></p>
<p>The effect of chronic daily administration of Edluar on oral tissue was evaluated in a 60-day open-label study in 60 insomniac patients. One patient developed transient sublingual <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and another transient <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of the tongue. </p>
<p><span class="Bold Italics">Adverse event incidence across the entire preapproval oral zolpidem database:</span></p>
<p>Zolpidem was administered to 3,660 subjects in clinical trials throughout the U.S., Canada, and Europe. Treatment-emergent adverse events associated with clinical trial participation were recorded by clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals experiencing treatment-emergent adverse events, similar types of untoward events were grouped into a smaller number of standardized event categories and classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms. </p>
<p>The frequencies presented, therefore, represent the proportions of the 3,660 individuals exposed to zolpidem, at all doses, who experienced an event of the type cited on at least one occasion while receiving zolpidem. All reported treatment-emergent adverse events are included, except those already listed in the table above of adverse events in placebo-controlled studies, those coding terms that are so general as to be uninformative, and those events where a drug cause was remote. It is important to emphasize that, although the events reported did occur during treatment with zolpidem, they were not necessarily caused by it. </p>
<p>Adverse events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.</p>
<p><span class="Italics">Autonomic nervous system:</span> Infrequent: increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. <br>Rare: abnormal accommodation, <span class="product-label-link" type="condition" conceptid="27587" conceptname="Disturbance of salivary secretion">altered saliva</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, increased saliva, tenesmus.</p>
<p><span class="Italics">Body as a whole:</span> Frequent: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>.  <br>Rare: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy aggravated</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, increased ESR, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless legs</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, tolerance increased, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>.</p>
<p><span class="Italics">Cardiovascular system:</span> Infrequent: <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.  <br>Rare: <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertension aggravated</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>.</p>
<p><span class="Italics">Central and peripheral nervous system:</span> Frequent: <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. <br>Infrequent: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, decreased cognition, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4238753" conceptname="Optical illusion">illusion</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, sleeping (after daytime dosing), speech disorder, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, appetite increased, decreased libido, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">dysphasia</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling strange</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>, intoxicated feeling, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>.</p>
<p><span class="Italics">Gastrointestinal system:</span> Frequent: <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <br>Infrequent: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="134681" conceptname="Diffuse spasm of esophagus">esophagospasm</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries</span>.</p>
<p><span class="Italics">Hematologic and lymphatic system:</span> Rare: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4049428" conceptname="Hemoglobinemia">hyperhemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4308125" conceptname="Macrocytic anemia">macrocytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
<p><span class="Italics">Immunologic system:</span> Infrequent: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> herpes simplex <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<p><span class="Italics">Liver and biliary system:</span> Infrequent: abnormal hepatic function, increased SGPT. <br>Rare: <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>.</p>
<p><span class="Italics">Metabolic and nutritional:</span> Infrequent: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesteremia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, increased alkaline phosphatase, increased BUN, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>.</p>
<p><span class="Italics">Musculoskeletal system:</span> Frequent: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="372409" conceptname="Sciatica">sciatica</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>.</p>
<p><span class="Italics">Reproductive system:</span> Infrequent: <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="4116072" conceptname="Fibroadenoma of breast">breast fibroadenosis</span>, breast neoplasm, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>.</p>
<p><span class="Italics">Respiratory system:</span> Frequent: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
<p><span class="Italics">Skin and appendages:</span> Infrequent: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, injection-site <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Special senses:</span> Frequent: <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span>, <span class="product-label-link" type="condition" conceptid="379814" conceptname="Dislocation of lacrimal gland">lacrimation abnormal</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">photopsia</span>.</p>
<p><span class="Italics">Urogenital system:</span> Frequent: <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>. <br>Rare: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, micturition frequency, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="KS070de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="KS071de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CNS-active Drugs</h2>
<p class="First">Co-administration of zolpidem with other CNS depressants increases the risk of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> <span class="Italics">[see Warnings and Precautions (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>)]</span>.  Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs.</p>
<p><span class="Italics">Imipramine, Chlorpromazine</span></p>
<p>Imipramine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness.  Similarly, chlorpromazine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>, but there was an additive effect of decreased alertness and psychomotor performance <span class="Italics">[see Clinical Pharmacology (<a href="#KS123de965605-268a-4479-86f7-84de949cf36f">12.3</a>)]</span>.</p>
<p><span class="Italics">Haloperidol</span></p>
<p>A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem.  The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration <span class="Italics">[see Clinical Pharmacology (<a href="#KS123de965605-268a-4479-86f7-84de949cf36f">12.3</a>)]</span>.</p>
<p><span class="Italics">Alcohol</span></p>
<p>An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated <span class="Italics">[see Warnings and Precautions (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>)]</span>.</p>
<p><span class="Italics">Sertraline</span></p>
<p>Concomitant administration of zolpidem and sertraline increases exposure to zolpidem and may increase the pharmacodynamics effect of zolpidem <span class="Italics">[see Clinical Pharmacology (<a href="#KS123de965605-268a-4479-86f7-84de949cf36f">12.3</a>)]</span>.</p>
<p><span class="Italics">Fluoxetine</span></p>
<p>After multiple doses of zolpidem tartrate and fluoxetine an increase in the zolpidem half-life (17%) was observed.  There was no evidence of an additive effect in psychomotor performance <span class="Italics">[see Clinical Pharmacology (<a href="#KS123de965605-268a-4479-86f7-84de949cf36f">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS072de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs That Affect Drug Metabolism Via Cytochrome P450</h2>
<p class="First">Some compounds known to inhibit CYP3A may increase exposure to zolpidem.  The effect of other P450 enzymes on the exposure to zolpidem is not known.</p>
<p><span class="Italics">Rifampin</span></p>
<p>Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamics effects of zolpidem.  Use of Rifampin in combination with zolpidem may decrease the efficacy of zolpidem.</p>
<p><span class="Italics">Ketoconazole</span></p>
<p>Ketoconazole, a potent CYP3A4 inhibitor, increased the pharmacodynamics effects of zolpidem.  Consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="KS080de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="KS081de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><span class="Bold Italics">Pregnancy Category C:</span></p>
<p>There are no adequate and well-controlled studies of Edluar in pregnant women. Studies in children to assess the effects of prenatal exposure to zolpidem have not been conducted; however, cases of severe <span class="product-label-link" type="condition" conceptid="4318857" conceptname="Neonatal respiratory depression">neonatal respiratory depression</span> have been reported when zolpidem was used at the end of pregnancy, especially when taken with other CNS-depressants.  Children born to mothers taking sedative-hypnotic drugs may be at risk for withdrawal symptoms during the postnatal period.  Neonatal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span> has also been reported in infants born to mothers who received sedative-hypnotic drugs during pregnancy.  Edluar should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. </p>
<p>Administration of zolpidem to pregnant rats and rabbits resulted in adverse effects on offspring development at doses greater than the maximum recommended human dose (MRHD) of 10 mg/day (approximately 8 mg/day zolpidem base); however, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was not observed.</p>
<p>When zolpidem was administered at oral doses of 4, 20, and 100 mg base/kg to pregnant rats during the period of organogenesis, dose-related decreases in fetal skull ossification occurred at all but the lowest dose, which is approximately 5 times the MRHD on a mg/m<span class="Sup">2</span> basis. In rabbits treated during organogenesis with zolpidem at oral doses of 1, 4, and 16 mg base/kg, increased embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and incomplete fetal skeletal ossification occurred at the highest dose. The no-effect dose for embryo-fetal toxicity in rabbits is approximately 10 times the MRHD on a mg/m<span class="Sup">2</span> basis. Administration of zolpidem to rats at oral doses of 4, 20, and 100 mg base/kg during the latter part of pregnancy and throughout lactation produced decreased offspring growth and survival at all but the lowest dose, which is approximately 5 times the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="KS082de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-8.2"></a><p></p>
<h2>8.2  Labor and Delivery</h2>
<p class="First">Edluar has no established use in labor and delivery <span class="Italics">[see Pregnancy (<a href="#KS081de965605-268a-4479-86f7-84de949cf36f">8.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="KS083de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Zolpidem is excreted in human milk. Caution should be exercised when Edluar is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="KS084de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-8.4"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Edluar is not recommended for use in children. Safety and effectiveness in pediatric patients have not been established in pediatric patients below the age of 18.</p>
<p>In an 8-week controlled study in 201 pediatric patients (aged 6-17 years) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> associated with attention-deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>), an oral solution of zolpidem tartrate dosed at 0.25mg/kg at bedtime did not decrease sleep latency compared to placebo. Ten patients on zolpidem (7.4%) discontinued treatment due to an adverse reaction.</p>
<p>Psychiatric and <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">nervous system disorders</span> comprised the most frequent (&gt;5%) treatment emergent adverse reactions observed with zolpidem versus placebo and included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (23.5% vs. 1.5%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (12.5% vs. 9.2%), and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> reported in 7% of the pediatric patients who received zolpidem; none of the pediatric patients who received placebo reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> <span class="Italics">[see Warnings and Precautions (<a href="#KS054de965605-268a-4479-86f7-84de949cf36f">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="KS085de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-8.5"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">A total of 154 patients in U.S. controlled clinical trials and 897 patients in non-U.S. clinical trials who received oral zolpidem were â‰¥60 years of age. For a pool of U.S. patients receiving  zolpidem tartrate at doses of â‰¤10 mg or placebo, there were three adverse events occurring at an incidence of at least 3% for zolpidem and for which the zolpidem incidence was at least twice the placebo incidence (i.e., they could be considered drug-related).</p>
<table width="400"><tbody class="Headless">
<tr class="First">
<td><span class="Bold">Adverse Event</span></td>
<td align="center"><span class="Bold">Zolpidem</span></td>
<td align="center"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">3%</td>
<td align="center">0%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td align="center">5%</td>
<td align="center">2%</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">3%</td>
<td align="center">1%</td>
</tr>
</tbody></table>
<p>A total of 30/1,959 (1.5%) non-U.S. patients receiving zolpidem tartrate reported <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>, including 28/30 (93%) who were â‰¥70 years of age. Of these 28 patients, 23 (82%) were receiving zolpidem doses &gt;10 mg.  A total of 24/1,959 (1.2%) non-U.S. patients receiving zolpidem reported <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, including 18/24 (75%) who were â‰¥70 years of age. Of these 18 patients, 14 (78%) were receiving zolpidem doses &gt;10 mg.</p>
<p>The dose of Edluar in elderly patients is 5 mg to minimize adverse effects related to impaired motor and/or cognitive performance and unusual sensitivity to sedative/hypnotic drugs <span class="Italics">[see Dosage and Administration (<a href="#KS020de965605-268a-4479-86f7-84de949cf36f">2</a>), Warnings and Precautions (<a href="#KS050de965605-268a-4479-86f7-84de949cf36f">5</a>) Clinical Pharmacology (<a href="#KS120de965605-268a-4479-86f7-84de949cf36f">12</a>) and Clinical Studies (<a href="#KS140de965605-268a-4479-86f7-84de949cf36f">14</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS727742-add6-11e2-9e96-0800200c9a66"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Gender Difference in Pharmacokinetics</h2>
<p class="First">Women clear zolpidem tartrate from the body at a lower rate than men, C<span class="Sub">max</span> and AUC parameters of zolpidem were approximately 45% higher at the same dose in female subjects compared with male subjects.  Given the higher blood levels of zolpidem tartrate in women compared to men at a given dose, the recommended dose of Edluar for adult women is 5 mg, and the recommended dose for adult men is 5 or 10 mg.</p>
<p>In geriatric patients, clearance of zolpidem is similar in men and women.  The recommended dose of Edluar in geriatric patients is 5 mg regardless of gender.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="KS090de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-9"></a><p></p>
<h1>9  DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="KS091de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-9.1"></a><p></p>
<h2>9.1  Controlled Substance</h2>
<p class="First">Edluar contains the same active substance, zolpidem tartrate, as zolpidem tartrate oral tablets and is classified as a Schedule IV controlled substance by federal regulation.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="KS092de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-9.2"></a><p></p>
<h2>9.2  Abuse</h2>
<p class="First">Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug effects over time. Tolerance may occur to both desired and undesired effects of drugs and may develop at different rates for different effects.</p>
<p>Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, using a multidisciplinary approach, but relapse is common.</p>
<p>Studies of abuse potential in former drug abusers found that the effects of single doses of zolpidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while zolpidem tartrate 10 mg was difficult to distinguish from placebo.</p>
<p>Because persons with a history of addiction to or abuse of, drugs or alcohol are at increased risk for misuse, abuse, and addiction of Edluar, they should be monitored carefully when receiving Edluar or any other hypnotic.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="KS093de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-9.3"></a><p></p>
<h2>9.3  <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.</p>
<p>Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to a withdrawal syndrome that may include abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The following adverse events which are considered to meet the DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal were reported during U.S. clinical trials following placebo substitution occurring within 48 hours following last zolpidem tartrate treatment: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>. These reported adverse events occurred at an incidence of 1% or less. However, available data cannot provide a reliable estimate of the incidence, if any, of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> during treatment at recommended doses. Post-marketing reports of abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and withdrawal have been received.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="KS100de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-10"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="KS101de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Signs and Symptoms</h2>
<p class="First">In postmarketing experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with zolpidem tartrate alone, or in combination with CNS-depressant agents, impairment of consciousness ranging from <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, cardiovascular and/or respiratory compromise, and fatal outcomes have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS102de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Recommended Treatment</h2>
<p class="First">Based on data obtained for zolpidem tartrate, general symptomatic and supportive measures for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Edluar should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Zolpidemâ€™s sedative/hypnotic effect was shown to be reduced by flumazenil and therefore may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>). As in all cases of drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.</p>
<p>As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="KS110de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-11"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">Edluar (zolpidem tartrate) sublingual tablet is a non-benzodiazepine hypnotic of the imidazopyridine class and is available in 5 mg and 10 mg strength tablets for sublingual administration.</p>
<p>Chemically, zolpidem tartrate is N,N,6-trimethyl-2-p-tolylimidazo[1,2-a] pyridine-3-acetamide L-(+)-tartrate (2:1). It has the following structure:</p>
<div class="Figure"><img alt="Chemical Structure of zolpidem tartrate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a32884d0-85b5-11de-8a39-0800200c9a66&amp;name=edluar-figure-1.jpg"></div>
<p>Zolpidem tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. It has a molecular weight of 764.88.</p>
<p>Each Edluar tablet includes the following inactive ingredients: mannitol, colloidal silicon dioxide, silicified microcrystalline cellulose, croscarmellose sodium, saccharin sodium, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="KS120de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-12"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="KS121de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-12.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Zolpidem, the active moiety of zolpidem tartrate, is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties. It interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes,  zolpidem <span class="Italics">in vitro</span> binds the BZ<span class="Sub">1</span> receptor preferentially with a high affinity ratio of the Î±<span class="Sub">1</span>/Î±<span class="Sub">5</span> subunits. This selective binding of zolpidem on the BZ<span class="Sub">1</span> receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem tartrate at hypnotic doses.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="KS123de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption:</span></p>
<p>Edluar (zolpidem tartrate) sublingual tablets are bioequivalent to Ambien<span class="Sup">Â®</span> tablets (Sanofi-Aventis) with respect to C<span class="Sub">max</span> and AUC. Similar to zolpidem tartrate oral tablets, Edluar sublingual tablets result in a pharmacokinetic profile characterized by rapid absorption.</p>
<p>Following administration of single 10 mg Edluar, in 18 healthy adult subjects (18-65 years of age), the mean peak concentration (C<span class="Sub">max</span>) of zolpidem was 106 ng/mL (range: 52 to 205 ng/ml) occurring at a median time (T<span class="Sub">max</span>) of 82 minutes (range: 30-180 min).</p>
<p>A food-effect study in 18 healthy volunteers compared the pharmacokinetics of Edluar 10 mg when administered while fasting or within 20 minutes after a high fat meal. The mean AUC and C<span class="Sub">max</span> were decreased by 20% and 31%, respectively, while median T<span class="Sub">max</span> was prolonged by 28% (from 82 to 105 min). The half-life remained unchanged. These results suggest that, for faster sleep onset, Edluar should not be administered with or immediately after a meal.</p>
<p><span class="Italics">Distribution:</span></p>
<p>Based on data obtained with oral zolpidem, the total protein binding was found to be 92.5 Â± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.</p>
<p><span class="Italics">Metabolism:</span></p>
<p>Based on data obtained with oral zolpidem, zolpidem is converted to inactive metabolites that are eliminated primarily by renal excretion. </p>
<p><span class="Italics">Elimination:</span></p>
<p>When Edluar administered as a single 5 or 10 mg dose in healthy adult subjects, the mean zolpidem elimination half-life was 2.85 hours (range: 1.57-6.73 hr) and 2.65 hours (range: 1.75 to 3.77 hr) respectively. </p>
<p><span class="Bold Italics">Special Populations</span></p>
<p><span class="Italics">Elderly:</span></p>
<p>In the elderly, the dose for Edluar should be 5 mg <span class="Italics">[see Warnings and Precautions (<a href="#KS050de965605-268a-4479-86f7-84de949cf36f">5</a>) and Dosage and Administration (<a href="#KS020de965605-268a-4479-86f7-84de949cf36f">2</a>)]</span>. This recommendation is based on several studies with zolpidem tartrate in which the mean C<span class="Sub">max</span>, T<span class="Sub">1/2</span>, and AUC were significantly increased when compared to results in young adults. In one study of eight elderly subjects (&gt;70 years), the means for C<span class="Sub">max</span>, T<span class="Sub">1/2</span>, and AUC significantly increased by 50% (255 vs. 384 ng/mL), 32% (2.2 vs. 2.9 hr), and 64% (955 vs. 1,562 ngâ€¢hr/mL), respectively, as compared to younger adults (20 to 40 years) following a single 20 mg oral dose. Zolpidem did not accumulate in elderly subjects following nightly oral dosing of 10 mg for 1 week.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span></p>
<p>The pharmacokinetics of zolpidem tartrate in eight patients with chronic <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> were compared to results in healthy subjects. Following a single 20-mg oral zolpidem tartrate dose, mean C<span class="Sub">max</span> and AUC were found to be two times (250 vs. 499 ng/mL) and five times (788 vs. 4,203 ngâ€¢hr/mL) higher, respectively, in hepatically-compromised patients. T<span class="Sub">max</span> did not change. The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normals of 2.2 hr (range: 1.6 to 2.4 hr). Dosing with Edluar should be modified accordingly in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics">[see Dosage and Administration (<a href="#KS022de965605-268a-4479-86f7-84de949cf36f">2.2</a>)]</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span></p>
<p>The pharmacokinetics of zolpidem tartrate were studied in 11 patients with end-stage 4 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (mean Cl<span class="Sub">Cr</span> = 6.5 Â± 1.5 mL/min) undergoing hemodialysis three times a week, who were dosed with zolpidem tartrate 10 mg orally each day for 14 or 21 days. No statistically significant differences were observed for C<span class="Sub">max</span>, T<span class="Sub">max</span>, half-life, and AUC between the first and last day of drug administration when baseline concentration adjustments were made.  Zolpidem was not hemodialyzable. No accumulation of unchanged drug appeared after 14 or 21 days. Zolpidem pharmacokinetics were not significantly different in renally-impaired patients. No dosage adjustment is necessary in patients with compromised renal function. </p>
<p><span class="Bold">Drug Interactions</span></p>
<p><span class="Italics">CNS-depressants:</span></p>
<p>Co-administration of zolpidem with other CNS depressants increases the risk of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> <span class="Italics">[see Warnings and Precautions (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>)]</span>.  Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs.  Imipramine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness.  Similarly, chlorpromazine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>, but there was an additive effect of decreased alertness and psychomotor performance.</p>
<p>A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem.  The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration.</p>
<p>An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated <span class="Italics">[see Warnings and Precautions (<a href="#KS051de965605-268a-4479-86f7-84de949cf36f">5.1</a>)]</span>.</p>
<p>Following five consecutive nightly doses at bedtime of oral zolpidem tartrate 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem C<span class="Sub">max</span> was significantly higher (43%) and T<span class="Sub">max</span> was significantly decreased (-53%).  Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.</p>
<p>A single-dose interaction study with zolpidem tartrate 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or pharmacodynamics interactions.  When multiple doses of zolpidem and fluoxetine were given at steady-state and the concentrations evaluated in healthy females, an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance.</p>
<p><span class="Italics">Drugs that Affect Drug metabolism via Cytochrome P450</span></p>
<p>Some compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes on the pharmacokinetics of zolpidem is unknown.</p>
<p>A single-dose interaction study with zolpidem tartrate 10 mg and itraconazole 200 mg at steady-state levels in male volunteers resulted in a 34% increase in AUC<span class="Sub">0-âˆž</span>  of zolpidem tartrate.  There were no pharmacodynamics effects of zolpidem detected on subjective <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, postural sway, or psychomotor performance.</p>
<p>A single-dose interaction study with zolpidem tartrate 10 mg and rifampin 600 mg at steady-state levels in female subjects showed significant reductions of the AUC (-73%), C<span class="Sub">max</span> (-58%), and T<span class="Sub">Â½</span> (-36 %) of zolpidem together with significant reductions in the pharmacodynamics effects of zolpidem tartrate.  Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamics effects of zolpidem.</p>
<p>A single-dose interaction study with zolpidem 5 mg and ketoconazole, a potent CYP3A4 inhibitor, given as 200 mg twice daily for 2 days increased C<span class="Sub">max</span> of zolpidem (30%) and the total AUC of zolpidem (70%) compared to zolpidem alone and prolonged the elimination half-life (30%) along with an increase in the pharmacodynamics effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together.</p>
<p><span class="Italics">Other Drugs with No Interactions with Zolpidem</span></p>
<p>A study involving cimetidine/zolpidem tartrate and ranitidine/zolpidem tartrate combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.</p>
<p>Zolpidem tartrate had no effect on digoxin pharmacokinetics and did not affect <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when given with warfarin in healthy subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="KS130de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-13"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="KS131de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold Italics">Carcinogenesis:</span></p>
<p>Zolpidem was administered to mice and rats for 2 years at oral doses of 4, 18, and 80 mg base/kg. In mice, these doses are approximately 2.5, 10, and 50 times the maximum recommended human dose (MRHD) of 10 mg/day (8 mg zolpidem base) on mg/m<span class="Sup">2</span> basis. In rats, these doses are approximately 5, 20, and 100 times the MRHD on a  mg/m<span class="Sup">2</span> basis.  No evidence of carcinogenic potential was observed in mice. In rats, renal tumors (<span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipoma</span>, liposarcoma) were seen at the mid- and high doses.</p>
<p><span class="Bold Italics">Mutagenesis:</span></p>
<p>Zolpidem was negative in <span class="Italics">in vitro</span> (bacterial reverse mutation, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and chromosomal aberration) and <span class="Italics">in vivo</span> (mouse micronucleus) genetic toxicology assays.</p>
<p><span class="Bold Italics">Impairment of Fertility:</span></p>
<p>Oral administration of zolpidem (doses of 4, 20, and 100 mg base/kg) to rats prior to and during mating, and continuing in females through postpartum day 25, resulted in irregular estrus cycles and prolonged precoital intervals at the highest dose tested. The no-effect dose for these findings is approximately 24 times the MRHD on a mg/m<span class="Sup">2</span> basis.  There was no impairment of fertility at any dose tested.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="KS140de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-14"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="KS141de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Transient Insomnia</span></h2>
<p class="First">Normal adults experiencing <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">transient insomnia</span> (n = 462) during the first night in a sleep laboratory were evaluated in a double-blind, parallel group, single night trial comparing two doses of zolpidem tartrate oral tablets (7.5 and 10 mg) and placebo.  Both zolpidem doses were superior to placebo on objective (polysomnographic) measures of sleep latency, sleep duration, and number of awakenings.</p>
<p>Normal elderly adults (mean age 68) experiencing <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">transient insomnia</span> (n = 35) during the first two nights in a sleep laboratory were evaluated in a double-blind, crossover, 2-night trial comparing four doses of zolpidem (5, 10, 15, and 20 mg) and placebo.  All zolpidem doses were superior to placebo on the two primary PSG parameters (sleep latency and efficiency) and all four subjective outcome measures (sleep duration, sleep latency, number of awakenings, and sleep quality).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS142de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-14.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Chronic Insomnia</span> </h2>
<p class="First">Zolpidem was evaluated in two controlled studies for the treatment of patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> (most closely resembling primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, as defined in the APA Diagnostic and Statistical Manual of <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Mental Disorders</span>, DSM-IVâ„¢).  Adult outpatients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> (n = 75) were evaluated in a double-blind, parallel group, 5-week trial comparing two doses of zolpidem tartrate and placebo. On objective (polysomnographic) measures of sleep latency and sleep efficiency, zolpidem 10 mg was superior to placebo on sleep latency for the first 4 weeks and on sleep efficiency for weeks 2 and 4. Zolpidem was comparable to placebo on number of awakenings at both doses studied.</p>
<p>Adult outpatients (n=141) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> were also evaluated, in a double-blind, parallel group, 4-week trial comparing two doses of zolpidem and placebo. Zolpidem 10 mg was superior to placebo on a subjective measure of sleep latency for all 4 weeks, and on subjective measures of total sleep time, number of awakenings, and sleep quality for the first treatment week. </p>
<p>Increased <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">wakefulness</span> during the last third of the night as measured by polysomnography has not been observed in clinical trials with zolpidem tartrate. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="KS143de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-14.3"></a><p></p>
<h2>14.3 Studies Pertinent to Safety Concerns for Sedative/Hypnotic Drugs </h2>
<p class="First"><span class="Bold Italics">Next-day residual effects:</span></p>
<p>Next-day residual effects of zolpidem tartrate were evaluated in seven studies involving normal subjects. In three studies in adults (including one study in a phase advance model of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">transient insomnia</span>) and in one study in elderly subjects, a small but statistically significant decrease in performance was observed in the Digit Symbol Substitution Test (DSST) when compared to placebo. Studies of zolpidem tartrate in non-elderly patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> did not detect evidence of next-day residual effects using the DSST, the Multiple Sleep Latency Test (MSLT), and patient ratings of alertness.</p>
<p><span class="Bold Italics">Rebound effects:</span></p>
<p>There was no objective (polysomnographic) evidence of rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> at recommended doses seen in studies evaluating sleep on the nights following discontinuation of zolpidem tartrate. There was subjective evidence of impaired sleep in the elderly on the first post-treatment night at doses of zolpidem tartrate above the recommended elderly dose of 5 mg. </p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory impairment</span>:</span></p>
<p>Controlled studies in adults utilizing objective measures of memory yielded no consistent evidence of next-day <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span> following the administration of zolpidem tartrate. However, in one study involving zolpidem doses of 10 and 20 mg, there was a significant decrease in next-morning recall of information presented to subjects during peak drug effect (90 minutes post-dose), i.e., these subjects experienced <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span>. There was also subjective evidence from adverse event data for <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span> occurring in association with the administration of zolpidem tartrate, predominantly at doses above 10 mg. </p>
<p><span class="Bold Italics">Effects on sleep stages:</span></p>
<p>In studies that measured the percentage of sleep time spent in each sleep stage, zolpidem tartrate has generally been shown to preserve sleep stages. Sleep time spent in stages 3 and 4 (deep sleep) was found comparable to placebo with only inconsistent, minor changes in REM (paradoxical) sleep at the recommended dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="KS160de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-15"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Edluar is supplied as sublingual tablets in two dosage strengths: Tablets are not scored.</p>
<p>Edluar 5 mg sublingual tablets are round white tablets, flat-faced, bevel-edged with debossed V on one side and supplied as:</p>
<p><span class="Bold">NDC NumberÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Size</span><br>
						0037-6050-30Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30</p>
<p>The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs consist of aluminum/aluminum Child Resistant Control (CRC) <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>.</p>
<p>Edluar 10 mg sublingual tablets are round white tablets, flat-faced, bevel-edged with debossed X on one side and supplied as:</p>
<p><span class="Bold">NDC NumberÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Size</span><br>
						0037-6010-30Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30</p>
<p>The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs consist of aluminum/aluminum Child Resistant Control (CRC) <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>.</p>
<p>Store at controlled room temperature 20-25Â°C (68-77Â°F). Protect from light and moisture.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="KS170de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-16"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling (<a href="#KS175de965605-268a-4479-86f7-84de949cf36f">Medication Guide</a>)</span>.</p>
<p>Inform patients and their families about the benefits and risks of treatment with Edluar.  Inform patients of the availability of a Medication Guide and instruct them to read the Medication Guide prior to initiating treatment with Edluar and with each prescription refill.  Review the Edluar Medication Guide with every patient prior to initiation of treatment.  Instruct patients or caregivers that Edluar should be taken only as prescribed.</p>
<p><span class="Italics">CNS-depressant Effects and Next-Day Impairment</span></p>
<p>Tell patients that Edluar has the potential to cause next-day impairment, and that this risk is increased if dosing instructions are not carefully followed.  Tell patients to wait for at least 8 hours after dosing before driving or engaging in other activities requiring full mental alertness.  Inform patients that impairment can be present despite feeling fully awake.</p>
<p>Â </p>
<p><span class="Italics">Severe Anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span></p>
<p>Inform patients that severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred with zolpidem. Describe the signs/symptoms of these reactions and advise patients to seek medical attention immediately if any of them occur. </p>
<p><span class="Italics">Sleep-Driving and Other Complex Behaviors</span></p>
<p>Instruct patients and their families that sedative hypnotics can cause <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> and behavior change, including â€œsleep-drivingâ€? and other complex behaviors while not being fully awake (preparing and eating food, making phone calls, or having sex).  Tell patients to call you immediately if they develop any of these symptoms. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></span></p>
<p>Tell patients to immediately report any suicidal thoughts.</p>
<p><span class="Italics">Alcohol and Other Drugs</span></p>
<p>Ask patients about alcohol consumption, medicines they are taking, and drugs they may be taking without a prescription.  Advise patients not to use Edluar if they drank alcohol that evening or before bed.</p>
<p><span class="Italics">Tolerance, Abuse, and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></span></p>
<p>Tell patients not to increase the dose of Edluar on their own, and to inform you if they believe the drug â€œdoes not workâ€?.</p>
<p><span class="Italics">Administration Instructions</span></p>
<p>Patients should be counseled to take Edluar right before they get into bed and only when they are able to stay in bed a full night (7-8 hours) before being active again. Edluar tablets should not be taken with or immediately after a meal. Advise patients NOT to take Edluar when drinking alcohol that evening or before bed. Edluar sublingual tablet should be placed under the tongue, where it will disintegrate.  The tablet should not be swallowed and the tablet should not be taken with water.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="KS175de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Medication Guide<br>
							Edluar<span class="Sup">Â®</span> [EDâ€™ â€“ loo-ahr]</span><br>
							(zolpidem tartrate)<br>
							sublingual tablets C-IV</p>
<p>Read this Medication Guide that comes with Edluar before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment.</p>
<p><a name="KS176de965605-268a-4479-86f7-84de949cf36f"></a><span class="Bold">What is the most important information I should know about Edluar?</span></p>
<ul>
<li><span class="Bold">Do not take more Edluar than prescribed.</span></li>
<li><span class="Bold">Do not take Edluar unless you are able to stay in bed a full night (7 to 8 hours) before you must be active again.</span></li>
<li><span class="Bold">Take Edluar right before you get in bed, not sooner</span></li>
</ul>
<p><span class="Bold">Edluar may cause serious side effects, including:</span></p>
<ul><li><span class="Bold">After taking Edluar, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. </span></li></ul>
<p>You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> with Edluar. Reported activities include:</p>
<ul class="Circle">
<li>driving a car (â€œsleep-drivingâ€?)</li>
<li>making and eating food</li>
<li>talking on the phone</li>
<li>having sex</li>
<li>sleep-walking</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if you find out that you have done any of the above activities after taking Edluar.</span></p>
<p><span class="Bold">Do not take Edluar if you:</span></p>
<ul>
<li>drank alcohol that evening or before bed</li>
<li>took another medicine to help you sleep </li>
</ul>
<p><span class="Bold">What is Edluar?</span></p>
<p>Edluar is a sedative-hypnotic (sleep) medicine. Edluar is used in adults for the short-term treatment of a <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problem</span> called <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (trouble <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep).<br> 
						It is not known if Edluar is safe and effective in children under the age of 18 years.</p>
<p>Edluar is a class four (C-IV) federally controlled substance because it can be abused or lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Keep Edluar in a safe place to prevent misuse and abuse. Selling or giving away Edluar may harm others, and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines or street drugs.</p>
<p><span class="Bold">Who should not take Edluar?</span></p>
<ul>
<li>Do not take Edluar if you are allergic to zolpidem or any other ingredients in Edluar.  See the end of this Medication Guide for a complete list of ingredients in Edluar.</li>
<li>Do not take Edluar if you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to drugs containing zolpidem, such as Ambien, Ambien CR, Zolpimist, or Intermezzo.</li>
</ul>
<p>Symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to zolpidem can include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, and throat that may cause <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> or swallowing</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking Edluar?</span></p>
<p><span class="Bold">Edluar may not be right for you. Before starting Edluar, tell your healthcare provider about all of your health conditions, including if you:</span><br></p>
<ul>
<li>have a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mental illness or, suicidal thoughts</li>
<li>have a history of drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> or addiction</li>
<li>have kidney or liver disease</li>
<li>have <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> or breathing problems</li>
<li>are pregnant or planning to become pregnant.  It is not known if Edluar will harm your unborn baby.</li>
<li>are breastfeeding or plan to breastfeed.  Edluar can pass into your breast milk.  It is not known if Edluar will harm your baby.  Talk to your healthcare provider about the best way to feed your baby while you take Edluar.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all of the medicines you take,</span> including prescription and nonprescription medicines, vitamins and herbal supplements.<br></p>
<p>Medicines can interact with each other, sometimes causing serious side effects. </p>
<p><span class="Bold">Do not take Edluar with other medicines that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, unless directed by your healthcare provider</span></p>
<p>Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How should I take Edluar?</span></p>
<ul>
<li>See "<span class="Bold"><a href="#KS176de965605-268a-4479-86f7-84de949cf36f">What is the most important information I should know about Edluar?</a></span>"</li>
<li>Take Edluar exactly as prescribed. Only take 1 Edluar tablet a night and only if needed.</li>
<li>Do not take Edluar if you drank alcohol that evening or before bed.</li>
<li>You should not take Edluar with or right after a meal.  Edluar may help you <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep faster if you take it on an empty stomach.</li>
<li>Do not use the tablet if the seal on the childproof <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack is broken, or if the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> holding the tablet is broken.</li>
<li>To open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack, separate the individual <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> at the perforations. Peel off the top layer of paper, and push the tablet through the foil. Alternatively, use scissors to open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.</li>
<li>Place the tablet under the tongue, where it will disintegrate. Do not swallow or take with water. </li>
<li>Call your healthcare provider if your <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problem</span>.</li>
<li>If you take too much Edluar or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, get emergency treatment.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Edluar?</span></p>
<p><span class="Bold">Edluar may cause serious side effects, including:</span><br></p>
<ul>
<li>
<span class="Bold">getting out of bed while not being fully awake and doing an activity that you do not know you are doing.</span>  See "<span class="Bold"><a href="#KS176de965605-268a-4479-86f7-84de949cf36f">What is the most important information I should know about Edluar?</a></span>"</li>
<li>
<span class="Bold">abnormal thoughts and behavior.</span>  Symptoms include more outgoing or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> than normal, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or actions.</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></span></li>
<li>
<span class="Bold">severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Symptoms include <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat, trouble
								breathing. Get emergency medical help if you get these symptoms after taking Edluar.
							</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if you have any of the above side effects or any other side effects that <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you while using Edluar. </span></p>
<p><span class="Bold">The most common side effects of Edluar are:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>grogginess or feeling as if you have been drugged</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
</ul>
<p>You may still feel drowsy the next day after taking Edluar.</p>
<p><span class="Bold">After you stop taking a sleep medicine</span>, you may have symptoms for 1 to 2 days such as: </p>
<ul>
<li>trouble sleeping</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span></li>
<li>uncontrolled <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></li>
<li>stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p>These are not all the side effects of Edluar. Ask your doctor or pharmacist for more information.</p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Edluar?</span></p>
<ul>
<li>Store Edluar at room temperature, between 68Â°F and 77Â°F (20Â° to 25Â°C). </li>
<li>	Protect from light and moisture.</li>
</ul>
<p>Keep Edluar and all medicines out of reach of children.</p>
<p><span class="Bold">General information about the safe and effective use of Edluar</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.<br>
						Do not use Edluar for a condition for which it was not prescribed.<br>
						Do not share Edluar with other people, even if you think they have the same symptoms that you have. It may harm them and it is against the law.</p>
<p>This Medication Guide summarizes the most important information about Edluar.</p>
<br><p>If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Edluar that is written for healthcare professionals.</p>
<p>For more information about Edluar, go to <span class="Underline">www.meda.us</span> or call Meda Pharmaceuticals Inc. at 1-866-444-7799</p>
<br><p><a name="KS177de965605-268a-4479-86f7-84de949cf36f"></a><span class="Bold">What are the ingredients in Edluar?</span></p>
<p><span class="Bold">Active Ingredient:</span> zolpidem tartrate</p>
<p><span class="Bold">Inactive Ingredients:</span> mannitol, colloidal silicon dioxide, silicified microcrystalline cellulose, croscarmellose sodium, saccharin sodium, and magnesium stearate. </p>
<p>This Medication Guide has been approved by U.S. Food and Drug Administration.</p>
<p>Â </p>
<p>Manufactured by:<br>
							Recipharm Stockholm AB, Sweden for Meda Pharmaceuticals Inc.
						</p>
<p>Â </p>
<p>Distributed by:<br>
							Meda Pharmaceuticals<br>
							Meda Pharmaceuticals Inc.<br>
							Somerset, NJ 08873-4120</p>
<p>Â©2014 Meda Pharmaceuticals Inc.Â Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Patents 6,761,910; 8,512,747;</p>
<p>MEDA PHARMACEUTICALS is a registered trademark of Meda AB.  EDLUAR is a registered trademark of Meda Pharmaceuticals Inc.</p>
<p>IG-6010-05Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Rev. 10/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="KS184de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel â€“ 30-Count Trade Carton for 5 mg Tablet</span></p>
<p><span class="Bold">Rx OnlyÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC</span> 0037-6050-30<br><span class="Bold">EDLUARâ„¢ 5 mgÂ Â Â CIV</span><br>
							Zolpidem Tartrate Sublingual Tablets<br>
							Each sublingual tablet (to be placed under the tongue) contains 5 mg<br>
							of zolpidem tartrate.  See prescribing information for dosage information.<br><span class="Bold">30 Sublingual Tablets</span><br>
							Federal Law requires dispensing of EDLUAR with the Medication Guide enclosed<br><span class="Bold">MEDA<br>
							PharmaceuticalsÂ®</span></p>
<p><img alt="30-Count Trade Carton for 5 mg Tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a32884d0-85b5-11de-8a39-0800200c9a66&amp;name=edluar-figure-2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="KS185de965605-268a-4479-86f7-84de949cf36f"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel â€“ 30-Count Trade Carton for 10 mg Tablet</span></p>
<p><span class="Bold">Rx OnlyÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC</span> 0037-6010-30<br><span class="Bold">EDLUARâ„¢ 10 mgÂ Â Â CIV</span><br>
								Zolpidem Tartrate Sublingual Tablets<br>
								Each sublingual tablet (to be placed under the tongue) contains 10 mg<br>
								of zolpidem tartrate.  See prescribing information for dosage information.<br><span class="Bold">30 Sublingual Tablets</span><br>
								Federal Law requires dispensing of EDLUAR with the Medication Guide enclosed<br><span class="Bold">MEDA<br>
								PharmaceuticalsÂ®</span></p>
<p><img alt="30-Count Trade Carton for 10 mg Tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a32884d0-85b5-11de-8a39-0800200c9a66&amp;name=edluar-figure-3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EDLUARÂ 		
					</strong><br><span class="contentTableReg">zolpidem tartrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0037-6050</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLPIDEM TARTRATE</strong> (ZOLPIDEM) </td>
<td class="formItem">ZOLPIDEM TARTRATE</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">V</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0037-6050-30</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021997</td>
<td class="formItem">07/24/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EDLUARÂ 		
					</strong><br><span class="contentTableReg">zolpidem tartrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0037-6010</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLPIDEM TARTRATE</strong> (ZOLPIDEM) </td>
<td class="formItem">ZOLPIDEM TARTRATE</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">X</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0037-6010-30</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0037-6010-02</td>
<td class="formItem">20  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021997</td>
<td class="formItem">07/24/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Meda Pharmaceuticals Inc.
							(051229602)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e1c9f570-33d4-11e4-8c21-0800200c9a66</div>
<div>Set id: a32884d0-85b5-11de-8a39-0800200c9a66</div>
<div>Version: 8</div>
<div>Effective Time: 20141031</div>
</div>
</div>Â <div class="DistributorName">Meda Pharmaceuticals Inc.</div></p>
</body></html>
